Summary
Which ophthalmic drugs lead the market in 2013? Will the same drugs be as
successful in 2018? How will this landscape change across the next 10 years?
Which trial drugs are likely to make an impact? Only one report will tell you
the answers. Simply by ordering and reading GMR Data’s new ‘Ophthalmic Drugs;
Data, Analysis and Forecasts to 2024’ report, you can stay ahead of your
competition. It really is that simple.
GMR Data forecasts that the global ophthalmic drugs market will reach $9.7bn by
2024. The US market growth will be slow compared to other markets predominantly
due to major drug patent expiry and generic erosion. For example;
• Xalabrands from Pfizer used for treatment of Glaucoma expired in the US in
March 2011.
• Azopt by Alcon used for treatment of Glaucoma expired in the US in October
2012.
• Lumigan by Allergan used for treatment of Glaucoma expired in the US in 2013.
• Restasis from Allergan used for treatment of Dry eye will expire in the US in
May 2014.
• Travatan by Alcon used for treatment of Glaucoma will expire in the US in
2014.
• Combigan by Allergan used for treatment of Glaucoma will expire in the US in
2022.
• Lucentis from Novartis used for treatment of Retinal Disorder will expire in
the US in June 2020.
Restasis by Allergan is the market-leading drug in the ophthalmic market with
sales of $1bn across 2013. Will it be able to see off the competition for the
next 5 years? The next 10 years? This report tells you. With an assessment of
the leading markets, such as the US, and EU, GMR Data examine how Germany and
France are the largest EU markets and what % of the global market they make up.
Which other countries contribute most? This report tells you in a concise,
focused and easily accessible format.
But how will these country’s markets develop? This report will tell you - TODAY
Global incidences of AMD, Glaucoma and Diabetic Retinopathy are all set to
increase dramatically across the forecast period of 2014-2024; this will have
the knock-on effect of driving sales of key drugs for treatment i.e. Lucentis
and Eylea, as well as driving R&D. How much is being spent on R&D – and which
drugs are likely to see a return? And how quickly?
Which new drugs will we see in the ophthalmic market across 2014-2024?
In December 2013 Santen announced that Ikervis (Ciclosporin / Cyclokat) was
filed to the EMA, in doing so the EMA will begin its regulatory process. Diquas,
which was launched in 2010 by Santen Pharma in Japan, China and other Asian
markets, and despite US trials being unsuccessful, is expected to gain approval
in the EU early in our forecast period.
Other key ophthalmic drugs currently under taking trials include;
• Sirolimus (By Santen, in Phase III US)
• Tafluprost/Timolol maleate (By Santen, filed for NDA)
• Catioprost (By Santen in Phase 2)
PLUS – In-depth country analysis – Discover which countries and regions will
drive the ophthalmic drugs market to 2024?
Exclusive Industry sourced information, not available anywhere else
As well as primary and secondary research sources, GMR Data have interviewed
leading ophthalmic specialists within big pharma, R&D, wholesalers,
distributors, marketeers and key clinical organisations. From these interviews
we have selected original, exclusive, transcribed interviews with leading
specialists in their field – This information is not available anywhere else.
Browse complete Report on:
http://www.aarkstore.com/healthcare/67271/ophthalmic-drugs-data-analysis-and-forecastsFor More Related Market Research Reports click here: Pharmaceuticals & Healthcare Market Research Reports
About Aarkstore.Com
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on Market Research Reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.
Contact Details:
Aarkstore Enterprise
Phone: +91 9987295242 / 022-27564953
Email: enquiry@aarkstore.com
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/
Latest News : http://www.aarkstore.com/news
Facebook: https://www.facebook.com/aarkstoredotcom
No comments:
Post a Comment